Vicente Arroyo

List of Publications by Year in descending order

475 papers	60,566 citations	588 125 h-index	1116 231 g-index
503 all docs	503 docs citations	503 times ranked	22369 citing authors

#	Article	IF	Citations
1	Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure. Journal of Hepatology, 2022, 76, 93-106.	3.7	51
2	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Regional Health - Europe, The, 2022, 12, 100240.	5.6	50
3	Novel APOB mutation in familial hypobetalipoproteinemia. Journal of Clinical Lipidology, 2022, 16, 28-32.	1.5	0
4	The role of RIPK1 mediated cell death in acute on chronic liver failure. Cell Death and Disease, 2022, 13, 5.	6.3	22
5	Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis. Journal of Hepatology, 2022, 76, 1079-1089.	3.7	37
6	Severe alcoholic hepatitis as precipitant for organ failure and ACLF. Zeitschrift Fur Gastroenterologie, 2022, 60, 67-76.	0.5	1
7	Albumin Lipidomics Reveals Meaningful Compositional Changes in Advanced Cirrhosis and Its Potential to Promote Inflammation Resolution. Hepatology Communications, 2022, 6, 1443-1456.	4.3	6
8	Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators. Frontiers in Immunology, 2022, 13, 842996.	4.8	11
9	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut, 2021, 70, gutjnl-2019-320170.	12.1	47
10	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acuteâ€onâ€chronic liver failure and acute decompensation. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 240-248.	2.8	11
11	Reply to: Correspondence on â€˜The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiologyâ€™. Journal of Hepatology, 2021, 74, 480-481.	3.7	9
12	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149
13	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. Journal of Hepatology, 2021, 74, 1117-1131.	3.7	45
14	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. Journal of Hepatology, 2021, 74, 670-685.	3.7	204
15	Albumin protects the liver from tumor necrosis factor Î±â€induced immunopathology. FASEB Journal, 2021, 35, e21365.	0.5	15
16	Elective Surgery but not Transjugular Intrahepatic Portosystemic Shunt Precipitates Acuteâ€Onâ€Chronic Liver Failure. Hepatology Communications, 2021, 5, 1265-1277.	4.3	9
17	Reply to: â€œSystemic inflammation and disorders of hemostasis in the AD-ACLF syndromeâ€. Journal of Hepatology, 2021, 74, 1265-1267.	3.7	2
18	Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute-on-chronic liver failure (ACLF). Digestive and Liver Disease, 2021, 53, 738-745.	0.9	5

#	Article	IF	Citations
19	New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. Journal of Hepatology, 2021, 75, S14-S26.	3.7	36
20	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 75, 1116-1127.	3.7	31
21	Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure. JHEP Reports, 2021, 3, 100355.	4.9	15
22	Efficacy of Albumin Treatment for Patients with CirrhosisÂandÂInfections Unrelated to Spontaneous BacterialÂPeritonitis. Clinical Gastroenterology and Hepatology, 2020, 18, 963-973.e14.	4.4	77
23	The Development and Outcome of Acuteâ€onâ€Chronic Liver Failure After Surgical Interventions. Liver Transplantation, 2020, 26, 227-237.	2.4	20
24	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	3.7	223
25	Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. Science Translational Medicine, 2020, 12, .	12.4	47
26	Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?. Journal of Hepatology, 2020, 73, 1316-1318.	3.7	8
27	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
28	Different inflammasome activation predisposes for acute-on-chronic liver failure depending on hepatic compensation in human and experimental liver cirrhosis. Journal of Hepatology, 2020, 73, S207-S208.	3.7	0
29	Liver Transplantation for Acuteâ€onâ€Chronic Liver Failure: Science or Fiction?. Liver Transplantation, 2020, 26, 906-915.	2.4	46
30	Acute-on-Chronic Liver Failure. New England Journal of Medicine, 2020, 382, 2137-2145.	27.0	353
31	Acuteâ€onâ€Chronic Liver Failure: A New Disease or an Old One Hiding in Plain Sight?. Clinical Liver Disease, 2020, 15, S45-S51.	2.1	12
32	Albumin in decompensated cirrhosis: new concepts and perspectives. Gut, 2020, 69, 1127-1138.	12.1	190
33	Reply to: â€œMetabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosisâ€. Journal of Hepatology, 2020, 73, 732-734.	3.7	0
34	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. Frontiers in Immunology, 2020, 11, 1352.	4.8	13
35	Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. Liver International, 2020, 40, 646-653.	3.9	10
36	Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. Journal of Hepatology, 2020, 73, 817-828.	3.7	48

#	Article	IF	Citations
37	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. Frontiers in Immunology, 2020, 11, 619039.	4.8	39
38	Liver Failure, Acute-on-Chronic. , 2020, , 436-443.		1
39	Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection. Critical Care Medicine, 2020, 48, e1350-e1355.	0.9	39
40	Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987956.	3.2	43
41	Left Ventricular Longitudinal Contractility Predicts Acuteâ€onâ€Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt. Hepatology Communications, 2019, 3, 340-347.	4.3	26
42	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology, 2019, 157, 149-162.	1.3	178
43	Review of Defective NADPH Oxidase Activity and Myeloperoxidase Release in Neutrophils From Patients With Cirrhosis. Frontiers in Immunology, 2019, 10, 1044.	4.8	11
44	EASL International Recognition Award Recipient 2019: Prof. Flair JosÃ© Carrilho. Journal of Hepatology, 2019, 70, 826-827.	3.7	0
45	Acute-on-Chronic Liver Failure in Cirrhosis Requires Expedited Decisions for Liver Transplantation. Gastroenterology, 2019, 156, 1248-1249.	1.3	12
46	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	4.8	134
47	An Accurate Data Preparation Approach for the Prediction of Mortality in ACLF Patients using the CANONIC Dataset. , 2019, 2019, 1371-1377.		5
48	Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt. Clinical and Translational Gastroenterology, 2019, 10, e00025.	2.5	87
49	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. Journal of Hepatology, 2019, 70, 398-411.	3.7	225
50	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. Hepatology, 2019, 69, 1686-1701.	7.3	80
51	Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Therapeutic Advances in Gastroenterology, 2019, 12, 1756284819879565.	3.2	6
52	The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis. Journal of Hepatology, 2018, 69, 318-324.	3.7	82
53	Acuteâ€onâ€Chronic Liver Failure: Getting Ready for Prime Time?. Hepatology, 2018, 68, 1621-1632.	7.3	86
54	The use of human albumin in patients with cirrhosis: a European survey. Expert Review of Gastroenterology and Hepatology, 2018, 12, 625-632.	3.0	14

#	Article	IF	Citations
55	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in PatientsÂWith Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 1792-1800.e3.	4.4	127
56	Acute-on-Chronic Liver Failure, Human Serum Albumin, and Immune Modulation: The Beginning of an Exciting Adventure. Clinical Gastroenterology and Hepatology, 2018, 16, 633-636.	4.4	6
57	Cell death markers in patients with cirrhosis and acute decompensation. Hepatology, 2018, 67, 989-1002.	7.3	76
58	Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut, 2018, 67, 1870-1880.	12.1	375
59	Dynamic Prognostication in Critically Ill Cirrhotic Patients With Multiorgan Failure in ICUs in Europe and North America: A Multicenter Analysis*. Critical Care Medicine, 2018, 46, 1783-1791.	0.9	45
60	Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogenâ€Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis. Hepatology, 2018, 68, 1937-1952.	7.3	70
61	Reply. Hepatology, 2017, 66, 294-294.	7.3	0
62	Microalbuminuria, systemic inflammation, and multiorgan dysfunction in decompensated cirrhosis: evidence for a nonfunctional mechanism of hepatorenal syndrome. Hepatology International, 2017, 11, 242-244.	4.2	11
63	The Legacy of Juan RodÃ©s (1938â€“2017), a European Leader in Hepatology and Clinical Research. Journal of Hepatology, 2017, 66, 675-676.	3.7	1
64	Short article. European Journal of Gastroenterology and Hepatology, 2017, 29, 535-538.	1.6	0
65	Plasma cystatin C is a predictor of renal dysfunction, acuteâ€onâ€chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology, 2017, 66, 1232-1241.	7.3	72
66	Response to the clinical course and shortâ€term mortality of cirrhotic patients with nonâ€spontaneous bacterial peritonitis infections. Liver International, 2017, 37, 623-623.	3.9	3
67	Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis. Journal of Hepatology, 2017, 66, 451-453.	3.7	21
68	Molecular Adsorbent Recirculating System Can Reduce Short-Term Mortality Among Patients With Acute-on-Chronic Liver Failureâ€”A Retrospective Analysis*. Critical Care Medicine, 2017, 45, 1616-1624.	0.9	52
69	Polymorphisms in the ILâ€1 gene cluster influence systemic inflammation in patients at risk for acuteâ€onâ€chronic liver failure. Hepatology, 2017, 65, 202-216.	7.3	39
70	Clinical course and shortâ€term mortality of cirrhotic patients with infections other than spontaneous bacterial peritonitis. Liver International, 2017, 37, 385-395.	3.9	39
71	LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. Scientific Reports, 2016, 6, 35610.	3.3	25
72	Brexit from current guideline recommendations?. Gut, 2016, 65, 1919.1-1919.	12.1	1

#	Article	IF	Citations
73	Acute-on-Chronic Liver Failure: Definition, Diagnosis, and Clinical Characteristics. Seminars in Liver Disease, 2016, 36, 109-116.	3.6	77
74	Acute-on-Chronic Liver Failure: A Distinct Clinical Condition. Seminars in Liver Disease, 2016, 36, 107-108.	3.6	23
75	Neuroinflammation in liver disease: sessional talks from ISHEN. Metabolic Brain Disease, 2016, 31, 1339-1354.	2.9	8
76	Systemic inflammation in decompensated cirrhosis: Characterization and role in acuteâ€onâ€chronic liver failure. Hepatology, 2016, 64, 1249-1264.	7.3	550
77	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. Journal of Immunology, 2016, 197, 3360-3370.	0.8	87
78	Reply to: â€œNon-selective beta-blockers for the patients with acute on chronic liver failureâ€• Journal of Hepatology, 2016, 65, 646.	3.7	0
79	Acute-on-chronic liver failure in cirrhosis. Nature Reviews Disease Primers, 2016, 2, 16041.	30.5	320
80	Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.. Scientific Reports, 2016, 6, 25487.	3.3	125
81	The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. Journal of Immunology, 2016, 197, 3755-3761.	0.8	91
82	Reply. Hepatology, 2016, 64, 987-987.	7.3	0
83	Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). Journal of Hepatology, 2016, 64, 813-822.	3.7	104
84	Reply to â€œKeep the sick from harm in spontaneous bacterial peritonitis: Dose of beta blockers mattersâ€• Journal of Hepatology, 2016, 64, 1456-1457.	3.7	0
85	Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis. Journal of Critical Care, 2016, 33, 62-70.	2.2	126
86	Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. Journal of Hepatology, 2016, 64, 574-582.	3.7	196
87	Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis. Gut, 2016, 65, 840-851.	12.1	14
88	Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transplantation, 2015, 21, 1347-1354.	2.4	48
89	Clinical Course of acuteâ€onâ€chronic liver failure syndrome and effects on prognosis. Hepatology, 2015, 62, 243-252.	7.3	493
90	Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. PLoS ONE, 2015, 10, e0128145.	2.5	97

#	Article	IF	Citations
91	Chemokine Receptor Ccr6 Deficiency Alters Hepatic Inflammatory Cell Recruitment and Promotes Liver Inflammation and Fibrosis. PLoS ONE, 2015, 10, e0145147.	2.5	19
92	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology, 2015, 62, 762-772.	7.3	230
93	Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 536-541.	7.1	185
94	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015, 64, 531-537.	12.1	405
95	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of Hepatology, 2015, 62, 968-974.	3.7	571
96	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015, 62, 831-840.	3.7	289
97	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. Journal of Hepatology, 2015, 63, 1272-1284.	3.7	463
98	Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. Journal of Hepatology, 2015, 62, S131-S143.	3.7	358
99	Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. Journal of Hepatology, 2015, 63, 593-600.	3.7	53
100	Corrigendum to â€œDiagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascitesâ€•[J Hepatol 2015;62:968â€“974]. Journal of Hepatology, 2015, 63, 290.	3.7	9
101	Acute-on-Chronic Liver Failure: A New Clinical Entity. Clinical Gastroenterology and Hepatology, 2015, 13, 836-841.	4.4	49
102	Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut, 2015, 64, 1616-1622.	12.1	86
103	Acute-on-Chronic Liver Failure: Recent Concepts. Journal of Clinical and Experimental Hepatology, 2015, 5, 81-85.	0.9	36
104	Acute-on-Chronic Liver Failure. , 2015, , 243-250.		0
105	Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. Critical Care, 2014, 18, 700.	5.8	41
106	Molecular interplay between Î”5/Î”6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut, 2014, 63, 344-355.	12.1	107
107	Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis. Nature Medicine, 2014, 20, 467-469.	30.7	13
108	In memory of Joan Cordoba. Liver International, 2014, 34, 819-819.	3.9	2

#	Article	IF	Citations
109	Type-1 hepatorenal syndrome associated with infections in cirrhosis: Natural history, outcome of kidney function, and survival. Hepatology, 2014, 59, 1505-1513.	7.3	68
110	Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). Journal of Hepatology, 2014, 60, 275-281.	3.7	259
111	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. Journal of Hepatology, 2014, 60, 1310-1324.	3.7	685
112	Human serum albumin, systemic inflammation, and cirrhosis. Journal of Hepatology, 2014, 61, 396-407.	3.7	398
113	Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. Journal of Hepatology, 2014, 60, 955-961.	3.7	100
114	CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut, 2014, 63, 1782-1792.	12.1	118
115	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. Journal of Hepatology, 2014, 61, 1038-1047.	3.7	741
116	The biliary epithelium gives rise to liver progenitor cells. Hepatology, 2014, 60, 1367-1377.	7.3	158
117	A Histologic Scoring System for Prognosis of Patients With AlcoholicÂHepatitis. Gastroenterology, 2014, 146, 1231-1239.e6.	1.3	353
118	Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. Journal of Hepatology, 2014, 61, 35-42.	3.7	98
119	Resolvin D1 primes the resolution process initiated by calorie restriction in obesityâ€induced steatohepatitis. FASEB Journal, 2014, 28, 836-848.	0.5	97
120	Toward an Improved Definition of Acute-on-Chronic Liver Failure. Gastroenterology, 2014, 147, 4-10.	1.3	255
121	Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. Journal of Hepatology, 2013, 59, 482-489.	3.7	232
122	Coordinate Functional Regulation between Microsomal Prostaglandin E Synthase-1 (mPGES-1) and Peroxisome Proliferator-activated Receptor Î³ (PPARÎ³) in the Conversion of White-to-brown Adipocytes. Journal of Biological Chemistry, 2013, 288, 28230-28242.	3.4	72
123	Automated low flow pump system for the treatment of refractory ascites: A multi-center safety and efficacy study. Journal of Hepatology, 2013, 58, 922-927.	3.7	114
124	Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology, 2013, 58, 1757-1765.	7.3	120
125	Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology, 2013, 58, 1742-1756.	7.3	87
126	Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut, 2013, 62, 452-460.	12.1	167

#	Article	IF	Citations
127	Reply to: â€œEffect of albumin on survival in septic cirrhotic patients other than spontaneous bacterial peritonitis. The question remains openâ€. Journal of Hepatology, 2013, 58, 640.	3.7	4
128	Acute kidney injury (AKI) in cirrhosis: Should we change current definition and diagnostic criteria of renal failure in cirrhosis?. Journal of Hepatology, 2013, 59, 415-417.	3.7	35
129	Reply to: â€œAcute-on-chronic liver failure â€“ Its definition remains unclearâ€. Journal of Hepatology, 2013, 59, 191.	3.7	2
130	Cell-specific PPARÎ³ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. Journal of Hepatology, 2013, 59, 1045-1053.	3.7	91
131	A new method for therapeutic paracentesis: The automated low flow pump system. Comments in the context of the history of paracentesis. Journal of Hepatology, 2013, 58, 850-852.	3.7	11
132	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9.	1.3	2,211
133	LEFT ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic hemodynamics and renal dysfunction. Journal of Hepatology, 2013, 58, 51-57.	3.7	129
134	Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology, 2013, 58, 1836-1846.	7.3	327
135	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology, 2013, 57, 1153-1162.	7.3	452
136	Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats. Gut, 2013, 62, 138-145.	12.1	47
137	Conservative medical treatment of ovarian hyperstimulation syndrome: a single center series and cost analysis study. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 686-691.	2.8	7
138	Acute-on-chronic liver failure: Is the definition ready for prime time?. Clinical Liver Disease, 2013, 2, 113-115.	2.1	3
139	Bacterial infections in cirrhosis: A growing problem with significant implications. Clinical Liver Disease, 2013, 2, 102-105.	2.1	29
140	Relationship between systemic hemodynamics, renal dysfunction, and fluid retention in cirrhosis. Clinical Liver Disease, 2013, 2, 120-122.	2.1	5
141	Acute Kidney Injury Is an Early Predictor of Mortality for Patients With Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2012, 10, 65-71.e3.	4.4	155
142	Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. Journal of Hepatology, 2012, 56, 1040-1046.	3.7	50
143	Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. Journal of Hepatology, 2012, 57, 267-273.	3.7	191
144	Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. Journal of Hepatology, 2012, 57, 759-765.	3.7	179

#	Article	IF	Citations
145	Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. Journal of Hepatology, 2012, 57, 1199-1206.	3.7	116
146	Acute-on chronic liver failure. Journal of Hepatology, 2012, 57, 1336-1348.	3.7	545
147	Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases. Annals of Hepatology, 2012, 11, 399-403.	1.5	10
148	Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. Hepatology, 2012, 55, 1551-1561.	7.3	498
149	Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology, 2012, 55, 1931-1941.	7.3	177
150	Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. Gastroenterology, 2011, 140, 488-496.e4.	1.3	311
151	Hepatorenal syndrome. Expert Opinion on Pharmacotherapy, 2011, 12, 1405-1417.	1.8	20
152	Management of hepatorenal syndrome in patients with cirrhosis. Nature Reviews Nephrology, 2011, 7, 517-526.	9.6	58
153	Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut, 2011, 60, 702-709.	12.1	359
154	The Amount of Alcohol Consumption Negatively Impacts Short-Term Mortality in Mexican Patients With Alcoholic Hepatitis. American Journal of Gastroenterology, 2011, 106, 1472-1480.	0.4	33
155	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. Journal of Hepatology, 2011, 55, 564-573.	3.7	96
156	Pathophysiological basis of albumin use in cirrhosis. Annals of Hepatology, 2011, 10, S6-S14.	1.5	33
157	Intensive care of the patient with cirrhosis. Hepatology, 2011, 54, 1864-1872.	7.3	215
158	Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype. Journal of Immunology, 2011, 187, 5408-5418.	0.8	360
159	Role for PPARÎ³ in obesityâ€induced hepatic steatosis as determined by hepatocyteâ€and macrophageâ€specific conditional knockouts. FASEB Journal, 2011, 25, 2538-2550.	0.5	325
160	Management of Renal Failure. , 2011, , 429-451.		0
161	Pathophysiological basis of albumin use in cirrhosis. Annals of Hepatology, 2011, 10 Suppl 1, S6-14.	1.5	8
162	Novel Definition of Hepatorenal Syndrome: Clinical Consequences. Frontiers of Gastrointestinal Research, 2010, , 122-129.	0.1	4

#	Article	IF	Citations
163	Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase. Prostaglandins and Other Lipid Mediators, 2010, 92, 54-61.	1.9	22
164	Matrix Metalloproteinase 2 in Reducedâ€Size Liver Transplantation: Beyond the Matrix. American Journal of Transplantation, 2010, 10, 1167-1177.	4.7	18
165	Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology, 2010, 51, 219-226.	7.3	211
166	Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology, 2010, 51, NA-NA.	7.3	96
167	Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology, 2010, 51, 974-985.	7.3	141
168	5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor Î±-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology, 2010, 51, 817-827.	7.3	86
169	Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology, 2010, 51, 1567-1576.	7.3	117
170	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology, 2010, 52, 1783-1790.	7.3	88
171	Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1980-1991.	7.3	59
172	Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. Liver International, 2010, 30, 31-41.	3.9	44
173	Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver International, 2010, 30, 1137-1142.	3.9	87
174	5-Lipoxygenase Activating Protein Signals Adipose Tissue Inflammation and Lipid Dysfunction in Experimental Obesity. Journal of Immunology, 2010, 184, 3978-3987.	0.8	139
175	Combined liver-kidney transplantation in patients with cirrhosis and chronic kidney disease. Nephrology Dialysis Transplantation, 2010, 25, 2356-2363.	0.7	15
176	Inactivation of extrahepatic vascular Akt improves systemic hemodynamics and sodium excretion in cirrhotic rats. Journal of Hepatology, 2010, 53, 1041-1048.	3.7	6
177	Are Angiotensin II Receptor Antagonists Useful Strategies in Steatotic and Nonsteatotic Livers in Conditions of Partial Hepatectomy under Ischemia-Reperfusion?. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 130-140.	2.5	39
178	Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. American Journal of Physiology - Renal Physiology, 2009, 297, G726-G734.	3.4	110
179	Human serum albumin: Not just a plasma volume expander. Hepatology, 2009, 50, 355-357.	7.3	25
180	Effect of angiotensin II and bradykinin inhibition in rat reduced-size liver transplantation. Liver Transplantation, 2009, 15, 313-320.	2.4	15

#	Article	IF	Citations
181	Obesityâ€induced insulin resistance and hepatic steatosis are alleviated by Ï‰â€3 fatty acids: a role for resolvins and protectins. FASEB Journal, 2009, 23, 1946-1957.	0.5	511
182	Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. Gastroenterology, 2009, 136, 1639-1650.	1.3	197
183	Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis. American Journal of Gastroenterology, 2009, 104, 1382-1389.	0.4	206
184	Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. American Journal of Physiology - Renal Physiology, 2009, 296, G147-G156.	3.4	79
185	Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. American Journal of Physiology - Renal Physiology, 2009, 296, G553-G562.	3.4	66
186	Renal Function in Liver Disease. , 2009, , 261-267.		0
187	Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome. , 2009, , 859-866.		0
188	Molecular adsorbents recirculating system (MARS) and the failing liver: A negative editorial for a positive trial?. Hepatology, 2008, 47, 2143-2144.	7.3	2
189	The hepatic apelin system: A new therapeutic target for liver disease. Hepatology, 2008, 48, 1193-1201.	7.3	113
190	Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized Study. Gastroenterology, 2008, 134, 1352-1359.	1.3	541
191	Portal Hypertension and Its Complications. Gastroenterology, 2008, 134, 1715-1728.	1.3	303
192	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgraduate Medical Journal, 2008, 84, 662-670.	1.8	504
193	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. American Journal of Gastroenterology, 2008, 103, 2747-2756.	0.4	268
194	Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 475-483.	2.5	150
195	Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. Journal of Lipid Research, 2008, 49, 2513-2523.	4.2	45
196	Pathogenesis and Treatment of Hepatorenal Syndrome. Seminars in Liver Disease, 2008, 28, 081-095.	3.6	171
197	Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury. Critical Care Medicine, 2008, 36, 1256-1266.	0.9	45
198	The Long-term Results of a Randomized Clinical Trial of Laparoscopy-assisted Versus Open Surgery for Colon Cancer. Annals of Surgery, 2008, 248, 1-7.	4.2	502

#	Article	IF	Citations
199	Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 778-786.	2.5	52
200	The Liver and the Kidney: Mutual Clearance or Mixed Intoxication. , 2007, 156, 17-23.		5
201	MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut, 2007, 56, 1283-1290.	12.1	180
202	Impaired extracellular matrix degradation in aortic vessels of cirrhotic rats. Journal of Hepatology, 2007, 46, 440-446.	3.7	16
203	Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. Journal of Hepatology, 2007, 46, 935-946.	3.7	135
204	Restricted use of albumin for spontaneous bacterial peritonitis. Gut, 2007, 56, 597-599.	12.1	111
205	Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity. Gastroenterology, 2007, 132, 687-697.	1.3	108
206	Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. Gastroenterology, 2007, 133, 818-824.	1.3	639
207	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. Gastroenterology, 2007, 133, 2019-2028.	1.3	41
208	Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology, 2007, 46, 1919-1926.	7.3	236
209	Gene Transduction of an Active Mutant of Akt Exerts Cytoprotection and Reduces Graft Injury After Liver Transplantation. American Journal of Transplantation, 2007, 7, 769-778.	4.7	16
210	Management of ascites and hepatic hydrothorax. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 55-75.	2.4	36
211	Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation. Gastroenterology, 2006, 130, 1135-1143.	1.3	179
212	Norfloxacin vs Ceftriaxone in the Prophylaxis of Infections in Patients With Advanced Cirrhosis and Hemorrhage. Gastroenterology, 2006, 131, 1049-1056.	1.3	402
213	Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. Journal of Hepatology, 2006, 45, 221-229.	3.7	3
214	Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology, 2006, 44, 1288-1295.	7.3	279
215	Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome. Hepatology, 2006, 44, 1555-1563.	7.3	49
216	New Treatments of Hepatorenal Syndrome. Seminars in Liver Disease, 2006, 26, 254-264.	3.6	33

#	Article	IF	Citations
217	Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. American Journal of Physiology - Renal Physiology, 2006, 291, G877-G884.	3.4	54
218	Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17Sâ€hydroxyâ€DHA. FASEB Journal, 2006, 20, 2537-2539.	0.5	194
219	Renal Dysfunction in Cirrhosis: Pathophysiology, Clinical Features and Therapy. , 2006, , 417-452.		1
220	The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. Liver International, 2005, 25, 429-437.	3.9	35
221	Sodium retention in cirrhotic rats is associated with increased renal abundance of sodium transporter proteins. Kidney International, 2005, 67, 622-630.	5.2	29
222	Sustained aquaretic effect of the V2 -AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. British Journal of Pharmacology, 2005, 146, 654-661.	5.4	15
223	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology, 2005, 41, 579-587.	7.3	79
224	MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology, 2005, 41, 1282-1289.	7.3	338
225	Reply:. Hepatology, 2005, 42, 238-238.	7.3	6
226	Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology, 2005, 42, 439-447.	7.3	537
227	A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology, 2005, 42, 627-634.	7.3	229
228	The selective cyclooxygenaseâ€2 inhibitor SCâ€236 reduces liver fibrosis by mechanisms involving nonâ€parenchymal cell apoptosis and PPARÎ³ activation. FASEB Journal, 2005, 19, 1120-1122.	0.5	129
229	Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut, 2005, 54, 522-527.	12.1	94
230	Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. Journal of Leukocyte Biology, 2005, 78, 871-878.	3.3	56
231	Refractory Ascites. Digestive Diseases, 2005, 23, 30-38.	1.9	31
232	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARÎ³. Influence of albumin. Journal of Hepatology, 2005, 42, 75-81.	3.7	34
233	Ascites from cirrhotic patients induces angiogenesis through the phosphoinositide 3-kinase/Akt signaling pathway. Journal of Hepatology, 2005, 43, 85-91.	3.7	13
234	Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. Journal of Hepatology, 2005, 43, 272-282.	3.7	78

#	Article	IF	Citations
235	Microarray Analysis of Endothelial Differentially Expressed Genes in Liver of Cirrhotic Rats. Gastroenterology, 2005, 129, 1686-1695.	1.3	40
236	Renal Failure in Patients With Cirrhosis and Sepsis Unrelated to Spontaneous Bacterial Peritonitis: Value of MELD Score. Gastroenterology, 2005, 129, 1944-1953.	1.3	232
237	Recent advances in hepatorenal syndrome. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2005, 26, 13-20.	0.0	0
238	Hepatorenal syndrome - how to assess response to treatment and nonpharmacological therapy. Alimentary Pharmacology and Therapeutics, 2004, 20, 49-54.	3.7	10
239	5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis. Comparative Hepatology, 2004, 3, S19.	0.9	4
240	Reply:. Hepatology, 2004, 39, 866-867.	7.3	0
241	Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology, 2004, 39, 1613-1622.	7.3	87
242	Effects of contrast media on renal function in patients with cirrhosis: A prospective study. Hepatology, 2004, 40, 646-651.	7.3	61
243	Management of Cirrhosis and Ascites. New England Journal of Medicine, 2004, 350, 1646-1654.	27.0	721
244	Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. Journal of Hepatology, 2004, 40, 140-146.	3.7	203
245	High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. Journal of Hepatology, 2004, 40, 424-430.	3.7	44
246	Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. Journal of Hepatology, 2004, 41, 384-390.	3.7	141
247	Clinical need for antidiuretic hormone antagonists in cirrhosis. Hepatology, 2003, 37, 13-15.	7.3	8
248	Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology, 2003, 38, 452-459.	7.3	73
249	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology, 2003, 38, 258-266.	7.3	744
250	Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology, 2003, 38, 1210-1218.	7.3	430
251	Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver disease. Prostaglandins and Other Lipid Mediators, 2003, 72, 19-33.	1.9	21
252	Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology, 2003, 38, 919-929.	7.3	186

#	Article	IF	Citations
253	Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology, 2003, 125, 117-125.	1.3	317
254	Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology, 2003, 125, 522-531.	1.3	121
255	Use of albumin in the management of patients with decompensated cirrhosis. Digestive and Liver Disease, 2003, 35, 668-672.	0.9	8
256	Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Practice and Research in Clinical Endocrinology and Metabolism, 2003, 17, 607-622.	4.7	67
257	Nitric Oxide Synthase 3-Dependent Vascular Remodeling and Circulatory Dysfunction in Cirrhosis. American Journal of Pathology, 2003, 162, 1985-1993.	3.8	69
258	Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. Journal of Hepatology, 2003, 38, 69-89.	3.7	223
259	Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. Journal of Hepatology, 2003, 38, 755-761.	3.7	38
260	Hepatorenal syndrome. Lancet, The, 2003, 362, 1819-1827.	13.7	543
261	Inhibition of 5â€lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB Journal, 2003, 17, 1745-1747.	0.5	67
262	Origins of cardiac dysfunction in cirrhosis. Gut, 2003, 52, 1392-1394.	12.1	16
263	Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology, 2003, 38, 919-929.	7.3	88
264	Renal Effects of Selective Cyclooxygenase Inhibition in Experimental Liver Disease. Advances in Experimental Medicine and Biology, 2003, 525, 133-136.	1.6	0
265	Aspirin (ASA) regulates 5â€lipoxygenase activity and peroxisome proliferatorâ€activated receptor Î±â€mediated CINCâ€1 release in rat liver cells: novel actions of lipoxin A4(LXA4) and ASAâ€triggered 15â€epiâ€LXA4. FASEB Journal, 2002, 16, 1937-1939.	0.5	58
266	Increased plasma levels of neuropeptide Y in hepatorenal syndrome. Journal of Hepatology, 2002, 36, 349-355.	3.7	23
267	Chronology of hemodynamic changes in asymptomatic in vitro fertilization patients and relationship with ovarian steroids and cytokines. Fertility and Sterility, 2002, 77, 1178-1183.	1.0	14
268	Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. Fertility and Sterility, 2002, 78, 1261-1267.	1.0	31
269	Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology, 2002, 122, 85-93.	1.3	222
270	Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment. Gastroenterology, 2002, 122, 1658-1676.	1.3	143

#	Article	IF	Citations
271	Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology, 2002, 123, 1839-1847.	1.3	523
272	Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure [Lancet 1956;2:1221â€“1225]. Journal of Hepatology, 2002, 36, 315-320.	3.7	22
273	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology, 2002, 36, 941-948.	7.3	8
274	Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Annals of Hepatology, 2002, 1, 72-79.	1.5	54
275	Invited Commentary. Current Gastroenterology Reports, 2002, 4, 1-4.	2.5	1
276	Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. British Journal of Pharmacology, 2002, 135, 891-900.	5.4	43
277	Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology, 2002, 35, 140-148.	7.3	788
278	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology, 2002, 36, 941-948.	7.3	497
279	Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology, 2002, 36, 1172-1179.	7.3	35
280	Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Annals of Hepatology, 2002, 1, 72-9.	1.5	11
281	A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology, 2001, 34, 46-52.	3.7	225
282	Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. Journal of Hepatology, 2001, 34, 222-229.	3.7	24
283	Human myofibroblastic hepatic stellate cells express Ca2+-activated K+ channels that modulate the effects of endothelin-1 and nitric oxide. Journal of Hepatology, 2001, 35, 739-748.	3.7	27
284	In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology, 2001, 33, 956-962.	7.3	57
285	Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis. Hepatology, 2001, 34, 487-493.	7.3	37
286	Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. Hepatology, 2001, 34, 671-676.	7.3	273
287	Increased activity of guanosine 3â€²-5â€²-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology, 2000, 31, 304-310.	7.3	18
288	Dysregulation of renal aquaporins and Na-Cl cotransporter in CCl4-induced cirrhosis. Kidney International, 2000, 58, 216-228.	5.2	75

#	ARTICLE	IF	CITATIONS
289	Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2000, 14, 927-943.	2.4	14
290	New treatments for hepatorenal syndrome. Liver Transplantation, 2000, 6, 287-289.	2.4	17
291	Hepatorenal syndrome. Liver Transplantation, 2000, 6, S63-S71.	2.4	31
292	Is there still a need for albumin infusions to treat patients with liver disease?. Gut, 2000, 46, 588-590.	12.1	26
293	MECHANISMS OF ASCITES FORMATION. Clinics in Liver Disease, 2000, 4, 447-465.	2.1	38
294	HEPATORENAL SYNDROME. Clinics in Liver Disease, 2000, 4, 487-507.	2.1	21
295	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology, 2000, 119, 794-805.	1.3	69
296	Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology, 2000, 118, 1149-1156.	1.3	459
297	Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology, 2000, 33, 43-48.	3.7	381
298	Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. Journal of Hepatology, 2000, 32, 157-170.	3.7	152
299	Ascites and Liver Test Abnormalities During Severe Ovarian Hyperstimulation Syndrome. American Journal of Gastroenterology, 1999, 94, 994-999.	0.4	39
300	Adrenomedullin and nitric oxide in menstrual and in vitro fertilization cycles. Relationship to estradiol. Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 626-631.	2.8	6
301	Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. Hepatology, 1999, 29, 1057-1063.	7.3	68
302	Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. Hepatology, 1999, 30, 501-509.	7.3	30
303	Nitric oxide production and inducible nitric oxide synthase expression in peritoneal macrophages of cirrhotic patients. Hepatology, 1999, 30, 670-676.	7.3	41
304	Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology, 1999, 116, 1167-1175.	1.3	61
305	Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects. Gastroenterology, 1999, 116, 161-167.	1.3	83
306	Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. American Journal of Gastroenterology, 1999, 94, 994-999.	0.4	11

#	Article	IF	Citations
307	Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. New England Journal of Medicine, 1999, 341, 403-409.	27.0	1,519
308	Adrenomedullin and nitric oxide in menstrual and in vitro fertilization cycles. Relationship to estradiol. Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 626-631.	2.8	13
309	Hepatorenal Syndrome. Journal of the American Society of Nephrology: JASN, 1999, 10, 1833-1839.	6.1	58
310	Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology, 1998, 27, 35-41.	7.3	296
311	Increased renal expression of nitric oxide synthase type III in cirrhotic rats with ascites. Hepatology, 1998, 27, 1191-1199.	7.3	18
312	Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality. Hepatology, 1998, 27, 1227-1232.	7.3	387
313	Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology, 1998, 28, 39-44.	7.3	138
314	Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology, 1998, 28, 416-422.	7.3	374
315	Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology, 1998, 115, 147-156.	1.3	63
316	Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology, 1998, 114, 336-343.	1.3	103
317	Contraction of human hepatic stellate cells activated in culture: A role for voltage-operated calcium channels. Journal of Hepatology, 1998, 29, 398-408.	3.7	54
318	Circulatory Dysfunction in Asymptomaticin VitroFertilization Patients. Relationship with Hyperestrogenemia and Activity of Endogenous Vasodilators1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1489-1493.	3.6	35
319	Gene Expression of Endothelin-1 and ET_A and ET_B Receptors in Human Cirrhosis: Relationship with Hepatic Hemodynamics. Journal of Vascular Research, 1998, 35, 186-193.	1.4	92
320	Haematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome. Human Reproduction, 1998, 13, 2406-2410.	0.9	38
321	Circulatory Dysfunction in Asymptomatic in Vitro Fertilization Patients. Relationship with Hyperestrogenemia and Activity of Endogenous Vasodilators. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1489-1493.	3.6	28
322	The kidney in liver disease. , 1998, , 927-940.		1
323	Hepatorenal Syndrome. Seminars in Liver Disease, 1997, 17, 233-247.	3.6	83
324	Pathogenesis of Ascites in Cirrhosis. Seminars in Liver Disease, 1997, 17, 175-189.	3.6	104

#	Article	IF	Citations
325	PATHOPHYSIOLOGY, COMPLICATIONS, AND TREATMENT OF ASCITES. Clinics in Liver Disease, 1997, 1, 129-155.	2.1	21
326	Practical Recommendations for the Treatment of Ascites and Its Complications. Drugs, 1997, 54, 571-580.	10.9	21
327	Nitric oxide production by peritoneal macrophages of cirrhotic rats: A host response against bacterial peritonitis. Gastroenterology, 1997, 112, 2056-2064.	1.3	33
328	Paracentesis-induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology, 1997, 113, 579-586.	1.3	288
329	Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. Gastroenterology, 1997, 113, 615-624.	1.3	81
330	Effect of bacterial lipopolysaccharide on endothelin-1 production in human vascular endothelial cells. Journal of Hepatology, 1997, 26, 81-87.	3.7	35
331	Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. Journal of Hepatology, 1997, 26, 88-95.	3.7	109
332	Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. Journal of Hepatology, 1997, 27, 645-653.	3.7	59
333	Urinary endothelin-like immunoreactivity in patients with cirrhosis. Journal of Hepatology, 1997, 27, 810-816.	3.7	15
334	Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trials of spironolactone versus placebo. Journal of Hepatology, 1997, 26, 614-620.	3.7	84
335	Management of ascites in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 723-733.	2.8	8
336	10 Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. Bailliere's Clinical Gastroenterology, 1997, 11, 365-385.	0.9	18
337	Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: Relationship with the activity of neurohormonal systems. Hepatology, 1997, 25, 1338-1342.	7.3	43
338	TIPS and refractory ascites. Lessons from the recent history of ascites therapy. Journal of Hepatology, 1996, 25, 221-223.	3.7	21
339	Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. Journal of Hepatology, 1996, 25, 916-923.	3.7	57
340	Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology, 1996, 111, 1002-1010.	1.3	528
341	Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology, 1996, 111, 1011-1017.	1.3	243
342	Treatment of severe ovarian hyperstimulation syndrome by a conservative medical approach. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 662-667.	2.8	24

#	Article	IF	Citations
343	Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology, 1996, 23, 164-176.	7.3	1,387
344	Urinary excretion of urodilatin in patients with cirrhosis. Hepatology, 1996, 24, 1428-1432.	7.3	23
345	Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology, 1996, 24, 1481-1486.	7.3	38
346	Spontaneous bacterial peritonitis in cirrhotic patients treated using paracentesis or diuretics: Results of a randomized study. Hepatology, 1995, 21, 340-344.	7.3	22
347	Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology, 1995, 21, 554-560.	7.3	88
348	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology, 1995, 21, 674-679.	7.3	171
349	Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis. Hepatology, 1995, 22, 124-131.	7.3	62
350	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology, 1995, 22, 479-487.	7.3	41
351	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology, 1995, 22, 753-758.	7.3	90
352	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology, 1995, 22, 915-920.	7.3	65
353	Immunoreactive endothelin plasma levels in severe ovarian hyperstimulation syndrome. Fertility and Sterility, 1995, 64, 65-68.	1.0	17
354	Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Diagnostic Microbiology and Infectious Disease, 1995, 22, 141-145.	1.8	21
355	Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology, 1995, 108, 1842-1848.	1.3	59
356	Aquaretic effect of the Î¹-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology, 1995, 109, 217-223.	1.3	44
357	Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. Journal of Hepatology, 1995, 22, 389-398.	3.7	49
358	Spontaneous bacterial peritonitis in cirrhotic patients treated using paracentesis or diuretics: Results of a randomized study*1. Hepatology, 1995, 21, 340-344.	7.3	11
359	Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis*1. Hepatology, 1995, 22, 124-131.	7.3	54
360	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels*1. Hepatology, 1995, 22, 479-487.	7.3	38

#	Article	IF	Citations
361	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis*1. Hepatology, 1995, 22, 753-758.	7.3	8
362	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis*1, *2. Hepatology, 1995, 22, 915-920.	7.3	4
363	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology, 1995, 21, 674-679.	7.3	10
364	Antidiuretic Hormone and the Pathogenesis of Water Retention in Cirrhosis with Ascites. Seminars in Liver Disease, 1994, 14, 44-58.	3.6	85
365	Management of Ascites and Renal Failure in Cirrhosis. Seminars in Liver Disease, 1994, 14, 82-96.	3.6	43
366	Spontaneous bacterial peritonitis in liver cirrhosis: Treatment and prophylaxis. Infection, 1994, 22, S167-S175.	4.7	32
367	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology, 1994, 19, 1095-1099.	7.3	111
368	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology, 1994, 20, 30-33.	7.3	55
369	Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. Hepatology, 1994, 20, 584-591.	7.3	43
370	Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: Prognostic value of resistive index. Hepatology, 1994, 20, 839-844.	7.3	124
371	Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology, 1994, 20, 948-954.	7.3	60
372	Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology, 1994, 20, 1495-1501.	7.3	526
373	Increased nitric oxideâ€"dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology, 1994, 20, 1615-1621.	7.3	86
374	Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. Journal of Hepatology, 1994, 20, 282-288.	3.7	80
375	Blunted natriuretic response to human urine extracts with Na+, K+-ATPase inhibiting activity in experimental cirrhosis. Journal of Hepatology, 1994, 20, 660-665.	3.7	1
376	Intracellular calcium concentration in vascular smooth muscle cells of rats with cirrhosis. Journal of Hepatology, 1994, 21, 521-526.	3.7	19
377	A European survey on the treatment of ascites in cirrhosis. Journal of Hepatology, 1994, 21, 667-672.	3.7	46
378	Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. Hepatology, 1994, 20, 584-591.	7.3	6

#	Article	IF	Citations
379	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites*1. Hepatology, 1994, 20, 30-33.	7.3	66
380	Effect of Dipyridamole on Kidney Function in Cirrhosis. Hepatology, 1993, 17, 59-64.	7.3	33
381	Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology, 1993, 17, 251-257.	7.3	215
382	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. Hepatology, 1993, 17, 788-793.	7.3	136
383	Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology, 1993, 17, 800-806.	7.3	63
384	Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide. Hepatology, 1993, 18, 367-372.	7.3	142
385	Pathogenesis of sodium retention in cirrhosis. Journal of Hepatology, 1993, 18, 147-150.	3.7	11
386	Mechanism of sodium retention and ascites formation in cirrhosis. Journal of Hepatology, 1993, 17, S24-S28.	3.7	33
387	Paracentesis in the management of cirrhotic ascites. Journal of Hepatology, 1993, 17, S14-S18.	3.7	28
388	Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. Journal of Hepatology, 1993, 17, 220-226.	3.7	73
389	Circulating levels of endothelin in cirrhosis. Gastroenterology, 1993, 104, 1485-1491.	1.3	198
390	Precision in nutritional diagnoses. Gastroenterology, 1993, 105, 1923.	1.3	1
391	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology, 1993, 105, 229-236.	1.3	820
392	Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology, 1993, 17, 251-257.	7.3	15
393	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction,. Hepatology, 1993, 17, 788-793.	7.3	14
394	Effect of dipyridamole on kidney function in cirrhosis,. Hepatology, 1993, 17, 59-64.	7.3	1
395	Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. Gastroenterology, 1992, 102, 1077-1079.	1.3	37
396	Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Gastroenterology, 1992, 102, 280-286.	1.3	44

#	Article	IF	Citations
397	Effects of somatostatin on renal function in cirrhosis. Gastroenterology, 1992, 103, 1868-1874.	1.3	54
398	Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology, 1992, 102, 2114-2119.	1.3	59
399	Carbon tetrachloride induced cirrhosis in rats: A useful tool for investigating the pathogenesis of ascites in chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 90-97.	2.8	70
400	Assessment of the renin-angiotensin system in cirrhotic patients. Journal of Hepatology, 1992, 15, 179-183.	3.7	59
401	Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. Journal of Hepatology, 1992, 14, 280-285.	3.7	63
402	Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide. Hepatology, 1992, 15, 343-349.	7.3	201
403	Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration. Hepatology, 1992, 16, 724-727.	7.3	204
404	TREATMENT OF ASCITES IN CIRRHOSIS. Gastroenterology Clinics of North America, 1992, 21, 237-256.	2.2	36
405	Severe ovarian hyperstimulation syndrome: role of peripheral vasodilation. Fertility and Sterility, 1991, 56, 1077-1083.	1.0	73
406	Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology, 1991, 100, 494-501.	1.3	78
407	Doses of endothelin have natriuretic effects in conscious rats with cirrhosis and ascites. Kidney International, 1991, 40, 182-187.	5.2	25
408	Effects of endothelin on renal haemodynamics and segmental sodium handling in conscious rats. Acta Physiologica Scandinavica, 1991, 141, 305-308.	2.2	17
409	Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachlorideâ€“induced cirrhosis. Hepatology, 1991, 13, 585-589.	7.3	40
410	Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites. Hepatology, 1991, 14, 601-607.	7.3	17
411	Paracentesis with Intravenous Infusion of Albumin as Compared with Peritoneovenous Shunting in Cirrhosis with Refractory Ascites. New England Journal of Medicine, 1991, 325, 829-835.	27.0	294
412	Neck â€œAscitesâ€•After Peritoneovenous Shunt. Journal of Clinical Gastroenterology, 1990, 12, 347-349.	2.2	0
413	Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome. Human Reproduction, 1990, 5, 348-351.	0.9	67
414	Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology, 1990, 98, 146-151.	1.3	208

#	Article	IF	Citations
415	Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Gastroenterology, 1990, 99, 1736-1744.	1.3	179
416	Effects of intravenous amino acid infusion and dietary proteins on kidney function in cirrhosis. Hepatology, 1990, 11, 379-386.	7.3	19
417	Natriuretic hormone activity in the urine of cirrhotic patients. Hepatology, 1990, 12, 467-475.	7.3	19
418	Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology, 1990, 12, 716-724.	7.3	587
419	Prostaglandins and the treatment of hepatorenal syndrome in cirrhosis. Journal of Hepatology, 1990, 11, 142-144.	3.7	14
420	Endotoxin-induced ascites formation in the rat: Partial mediation by platelet-activating factor. Hepatology, 1989, 10, 788-794.	7.3	20
421	Treatment of ascites and renal failure in cirrhosis. Bailliere's Clinical Gastroenterology, 1989, 3, 165-186.	0.9	5
422	Role of altered systemic hemodynamics in the blunted renal response to atrial natriuretic peptide in rats with cirrhosis and ascites. Journal of Hepatology, 1989, 9, 217-226.	3.7	29
423	Effects of atrial natriuretic peptide on urinary kallikrein excretion and renal function in rats. European Journal of Pharmacology, 1989, 168, 1-6.	3.5	3
424	Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology, 1989, 97, 1294-1299.	1.3	63
425	Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors. Hepatology, 1988, 8, 27-31.	7.3	383
426	Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology, 1988, 8, 636-642.	7.3	170
427	Comparative study of aminoglycoside nephrotoxicity in normal rats and rats with experimental cirrhosis. Hepatology, 1988, 8, 837-844.	7.3	11
428	Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology, 1988, 8, 1151-1157.	7.3	1,513
429	Ruthenium-palladium catalysts: The effect of palladium on the catalytic behaviour of ruthenium. Applied Catalysis, 1988, 44, 1-9.	0.8	13
430	Pathophysiology of ascites and functional renal failure in cirrhosis. Journal of Hepatology, 1988, 6, 239-257.	3.7	71
431	Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology, 1988, 94, 482-487.	1.3	438
432	Longitudinal study of renal prostaglandin excretion in cirrhotic rats: Relationship with the reninâ€“aldosterone system. Clinical Science, 1988, 75, 263-269.	4.3	15

#	Article	IF	Citations
433	Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology, 1988, 94, 1493-1502.	1.3	599
434	Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Gastroenterology, 1987, 93, 234-241.	1.3	463
435	Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). Journal of Hepatology, 1987, 4, 293-298.	3.7	43
436	Compensated cirrhosis: Natural history and prognostic factors. Hepatology, 1987, 7, 122-128.	7.3	972
437	Treatment of Ascites. , 1987, , 291-295.		0
438	Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: An overview with emphasis on pathogenesis. American Journal of Medicine, 1986, 81, 104-122.	1.5	132
439	Urinary excretion of 6-keto-prostaglandin F1Î±, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Journal of Hepatology, 1986, 3, 111-117.	3.7	105
440	Treatment of ascites in patients with cirrhosis of the liver. Journal of Hepatology, 1986, 2, 504-512.	3.7	13
441	Sulindac Reduces the Urinary Excretion of Prostaglandins and Impairs Renal Function in Cirrhosis with Ascites. Nephron, 1986, 42, 298-303.	1.8	66
442	Management of Patients with Cirrhosis and Ascites. Seminars in Liver Disease, 1986, 6, 353-369.	3.6	38
443	Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology, 1985, 5, 245-250.	7.3	117
444	Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology, 1985, 5, 457-462.	7.3	299
445	Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology, 1985, 5, 463-467.	7.3	250
446	PARACENTESIS VERSUS DIURETICS IN THE TREATMENT OF CIRRHOTICS WITH TENSE ASCITES. Lancet, The, 1985, 325, 611-612.	13.7	102
447	Effect of Demeclocycline on Renal Function and Urinary Prostaglandin E₂ and Kallikrein in Hyponatremic Cirrhotics. Nephron, 1984, 36, 30-37.	1.8	36
448	Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney International, 1984, 26, 72-80.	5.2	121
449	Reticuloendothelial System Phagocytic Activity in Cirrhosis and Its Relation to Bacterial Infections and Prognosis. Hepatology, 1984, 4, 53-58.	7.3	442
450	Renal Kallikrein Excretion in Cirrhotics with Ascites: Relationship to Renal Hemodynamics. Hepatology, 1984, 4, 247-252.	7.3	54

#	Article	IF	Citations
451	Sympathetic nervous activity, reninâ€angiotensin system and renal excretion of prostaglandin E₂ in cirrhosis. Relationship to functional renal failure and sodium and water excretion. European Journal of Clinical Investigation, 1983, 13, 271-278.	3.4	211
452	Aminoglycoside nephrotoxicity in cirrhosis. Gastroenterology, 1982, 82, 97-105.	1.3	160
453	Plasma Renin Activity and Urinary Sodium Excretion as Prognostic Indicators in Nonazotemic Cirrhosis with Ascites. Annals of Internal Medicine, 1981, 94, 198.	3.9	102
454	Effect of angiotensinâ€II blockade on systemic and hepatic haemodynamics and on the reninâ€angiotensinâ€aldosterone system in cirrhosis with ascites. European Journal of Clinical Investigation, 1981, 11, 221-229.	3.4	149
455	Intracellular and exchangeable potassium in cirrhosis. Digestive Diseases and Sciences, 1981, 26, 723-727.	2.3	13
456	Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology, 1980, 78, 92-99.	1.3	253
457	Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.. Gut, 1980, 21, 855-859.	12.1	18
458	Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. European Journal of Clinical Investigation, 1979, 9, 69-73.	3.4	107
459	Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis.. Gut, 1977, 18, 556-560.	12.1	84
460	Incorporation of amino acids into the cyclohexadepsipeptide, monamycin. Journal of the Chemical Society Chemical Communications, 1976, , 845.	2.0	13
461	Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. The American Journal of Digestive Diseases, 1976, 21, 249-256.	0.9	168
462	Ascites and renal failure in primary liver cell carcinoma.. BMJ: British Medical Journal, 1975, 3, 629-629.	2.3	7
463	Hypernatremia following gastrointestinal bleeding in cirrhosis with ascites. The American Journal of Digestive Diseases, 1975, 20, 127-133.	0.9	6
464	Clinical types and drug therapy of renal impairment in cirrhosis. Postgraduate Medical Journal, 1975, 51, 492-497.	1.8	52
465	Clinical experience with the RhÃ´ne-Poulenc ascites reinfusion apparatus. Postgraduate Medical Journal, 1975, 51, 571-572.	1.8	10
466	A rational approach to the treatment of ascites. Postgraduate Medical Journal, 1975, 51, 558-562.	1.8	62
467	The biosynthetic origin of D-isoleucine in the monamycins. Journal of the Chemical Society Chemical Communications, 1973, , 782.	2.0	6
468	Letter: Ascites and oedema in liver disease.. BMJ: British Medical Journal, 1973, 4, 232-232.	2.3	0

#	Article	IF	Citations
469	Experimental Models of Spontaneous Bacterial Peritonitis. , 0, , 409-421.		1
470	Medical Treatment of Ascites in Cirrhosis. , 0, , 227-240.		6
471	Prognosis of Patients with Cirrhosis and Ascites. , 0, , 260-270.		36
472	Liver Transplantation for Patients with Cirrhosis and Ascites. , 0, , 271-285.		5
473	Hepatorenal Syndrome in Cirrhosis: Clinical Features, Diagnosis, and Management. , 0, , 341-359.		3
474	Nitric Oxide and Systemic and Renal Hemodynamic Disturbances in Cirrhosis. , 0, , 105-114.		1
475	The Effect of Liver Disease on the Urogenital Tract. , 0, , 1815-1821.		0